Indian govt tees off series of meetings to build robust pharma regulatory systems

Even as the US Food and Drug Administration’s (FDA) director of drug quality Carmelo Rosa recently emphasized the need for Indian pharmaceutical companies to continually strive to manufacture drugs of the highest quality, both domestically and internationally, the Indian government has gone into overdrive to ensure that the impeccable standards of its regulatory mechanisms can be maintained over the long-term, reports The Pharma Letter’s India correspondent.

In order to build robust and resilient regulatory systems, the government has begun a series of meetings with drug regulators, senior government policy officials, pharma industry representatives, and stakeholders.

The meetings, called 'Chintan Shivir' (meaning contemplation camps) are intended to deliberate on pathways to develop robust and resilient regulatory systems through cohesive and synergistic approaches.